We are live on ! Find out more
DAWN icon

Day One Biopharmaceuticals

Delisted

DAWN was delisted on the 22nd of April, 2026.

184 hedge funds and large institutions have $747M invested in Day One Biopharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 69 increasing their positions, 46 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 21

50% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 46

12% more funds holding

Funds holding: 164 → 184 (+20)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% less ownership

Funds ownership: 92.95% → 92.94% (-0%)

6% less capital inflows, than outflows

Capital inflows: $164M | Capital outflows: $175M

30% less call options, than puts

Call options by funds: $1.23M | Put options by funds: $1.76M

Holders
184
Holders Change
+20
Holders Change %
+12.2%
% of All Funds
2.46%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
41
Increased
69
Reduced
46
Closed
21
Calls
$1.23​M
Puts
$1.76​M
Net Calls
-⁠$533​K
Net Calls Change
+$742​K

DAWN Hedge Fund Activity: Q1 2025 in Review

184 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q1 2025, worth a combined $747M — down 37% from $1.19B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new DAWN positions and 21 closed out — a net gain of 20 holders — while 69 added to existing stakes and 46 trimmed.

The largest buyer was Polar Capital Holdings, adding an estimated $23.3M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $39.3M sold.

  • 184 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q1 2025, up from 164 in Q4 2024.
  • Funds reported $747M of Day One Biopharmaceuticals stock for Q1 2025, down 37% quarter-over-quarter.
  • 41 funds opened new Day One Biopharmaceuticals positions in Q1 2025 and 21 closed out, a net change of +20 holders.
  • The largest Day One Biopharmaceuticals buyer in Q1 2025 was Polar Capital Holdings, an estimated $23.3M added.
  • The largest Day One Biopharmaceuticals seller in Q1 2025 was Fairmount Funds Management, an estimated $39.3M sold.

Based on aggregated 13F filings for Q1 2025.